Table 1.
Immunoreactivity against in vitro expressed TDRD6 correlated to clinical manifestations in 86 patients with APS1
| Clinical manifestation | Number with manifestation/total | Number with autoantibodies to TDRD6/total |
P* | |
|---|---|---|---|---|
| With manifestation | Without manifestation | |||
| Mucocutaneous candidiasis | 83/86 | 40/83 | 2/3 | 0.612 |
| Hypoparathyroidism | 71/86 | 37/71 | 5/15 | 0.258 |
| Adrenal insufficiency | 69/86 | 35/69 | 7/17 | 0.591 |
| Alopecia areata | 29/86 | 15/29 | 27/57 | 0.820 |
| Gonadal failure | 28/86 | 17/28 | 25/58 | 0.168 |
| Intestinal dysfunction | 22/86 | 12/22 | 30/64 | 0.624 |
| Vitiligo | 18/86 | 8/18 | 34/68 | 0.793 |
| Chronic active hepatitis | 16/86 | 10/16 | 32/70 | 0.274 |
| Pernicious anemia | 13/86 | 7/13 | 35/73 | 0.769 |
| Type 1 diabetes mellitus | 10/86 | 5/10 | 37/76 | 1.000 |
| Pituitary insufficiency | 6/86 | 2/6 | 40/80 | 0.677 |
*Calculated by use of two-tailed Fisher's exact test.